Darolutamide with or without hormone therapy before prostate cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your prostate cancer must be confirmed by a biopsy and be classified as high-risk or very high-risk.
- You can have had up to 6 months of standard hormone therapy before, but no chemotherapy, other targeted therapy, or past surgery to remove the testicles.
- Your tumor must be considered removable by surgery, meaning a doctor thinks the edges look clear and it hasn't spread into the bladder neck or urethra.
- You need to be healthy enough for surgery and daily activities (ECOG status 0-1) without serious heart or mental health problems.
- Men must be willing to use effective birth control (condoms with spermicide) during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This study looks at combining a drug called darolutamide with standard hormone therapy for men whose prostate cancer has spread to the lymph nodes after surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.